Autobio Diagnostics Co., Ltd. (603658.SS)
CNY 44.66
(-3.17%)
CNY 44.66
(-3.17%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 24.63 Million CNY | 51.52% |
| 2022 | 16.25 Million CNY | -37.84% |
| 2021 | 26.15 Million CNY | 43886610009292700.0% |
| 2020 | - CNY | -100.0% |
| 2019 | 503.05 Million CNY | 1089.54% |
| 2018 | 42.29 Million CNY | 24.31% |
| 2017 | 34.02 Million CNY | 913217421312000000.0% |
| 2016 | - CNY | -100.0% |
| 2015 | 70.03 Million CNY | 123.36% |
| 2014 | 31.35 Million CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 24.55 Million CNY | -61.58% |
| 2024 Q1 | 240.16 Million CNY | 675.14% |
| 2024 Q3 | 23.41 Million CNY | -100.0% |
| 2023 Q3 | 79.52 Million CNY | 15.11% |
| 2023 Q4 | 24.63 Million CNY | -69.02% |
| 2023 FY | 24.63 Million CNY | 51.52% |
| 2023 Q1 | 132.46 Million CNY | 714.74% |
| 2023 Q2 | 69.08 Million CNY | -47.85% |
| 2022 Q4 | 16.25 Million CNY | -20.7% |
| 2022 Q3 | 20.5 Million CNY | -9.63% |
| 2022 Q2 | 22.68 Million CNY | -7.7% |
| 2022 FY | 16.25 Million CNY | -37.84% |
| 2022 Q1 | 24.58 Million CNY | -6.03% |
| 2021 Q1 | 16.72 Million CNY | 28053801952870300.0% |
| 2021 Q3 | 29.74 Million CNY | 27.57% |
| 2021 Q4 | 26.15 Million CNY | -12.06% |
| 2021 FY | 26.15 Million CNY | 43886610009292700.0% |
| 2021 Q2 | 23.31 Million CNY | 39.44% |
| 2020 Q2 | 1.00 CNY | 0.0% |
| 2020 Q3 | - CNY | -100.0% |
| 2020 FY | - CNY | -100.0% |
| 2020 Q4 | - CNY | 300.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2019 Q4 | 503.05 Million CNY | 1.92% |
| 2019 FY | 503.05 Million CNY | 1089.54% |
| 2019 Q3 | 493.58 Million CNY | 6624783727643853000.0% |
| 2019 Q2 | - CNY | -100.0% |
| 2019 Q1 | 42.29 Million CNY | 0.0% |
| 2018 Q2 | 49.95 Million CNY | 46.83% |
| 2018 Q4 | 42.29 Million CNY | -0.24% |
| 2018 FY | 42.29 Million CNY | 24.31% |
| 2018 Q3 | 42.39 Million CNY | -15.14% |
| 2018 Q1 | 34.02 Million CNY | 0.0% |
| 2017 Q2 | - CNY | 0.0% |
| 2017 Q1 | - CNY | 100.0% |
| 2017 Q3 | 37.8 Million CNY | 0.0% |
| 2017 Q4 | 34.02 Million CNY | -10.0% |
| 2017 FY | 34.02 Million CNY | 913217421312000000.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q3 | 1.00 CNY | -100.0% |
| 2016 Q4 | - CNY | -100.0% |
| 2016 FY | - CNY | -100.0% |
| 2016 Q2 | 51.69 Million CNY | 0.0% |
| 2015 Q1 | 69.3 Million CNY | 0.0% |
| 2015 FY | 70.03 Million CNY | 123.36% |
| 2015 Q4 | 70.03 Million CNY | 0.0% |
| 2015 Q2 | 69.3 Million CNY | 0.0% |
| 2015 Q3 | - CNY | -100.0% |
| 2014 FY | 31.35 Million CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 1.1 Billion CNY | 97.766% |
| Joinn Laboratories(China)Co.,Ltd. | 41.92 Million CNY | 41.238% |
| WuXi AppTec Co., Ltd. | 687.01 Million CNY | 96.414% |
| Thalys Medical Technology Group Inc. | 596.75 Million CNY | 95.872% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 267.61 Million CNY | 90.794% |
| Chemclin Diagnostics Co., Ltd. | 227.94 Million CNY | 89.192% |